This researcher has some ideas about what we need to do to address the problem.
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
The risk of transmitting HIV through the breastmilk of virally suppressed women in high-income countries is not known.
This recently updated fact sheet from the U.S. Centers for Disease Control and Prevention provides a quick rundown of the latest HIV infection numbers and prevention challenges impacting new moms and moms-to-be.
No HIV-exposed infants who were negative at birth, whose mothers started ART before delivery, had suppressed viral loads, and exclusively breastfed, were HIV positive after breastfeeding, in a rural African cohort.
VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding
Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial ...